The effect of fenofibrate for seizure control in epilepsy patients

Investigating the effect of fenofibrate for seizure control in refractory epilepsy patients

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

IRCT

Registry ID

IRCT20200825048515N63

Enrollment

Registered

2023-01-17

Start date

2023-02-19

Completion date

Unknown

Last updated

2023-02-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Refractory epilepsy. Epilepsy, unspecified, intractable

Interventions

Intervention group: In this group, the dosage of fenofibrate drug starts with 100 mg daily, and if the seizures are not controlled, it is increased to 200 mg per day after two weeks..

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Epilepsy patients Age more than 18 years Resistant to at least two anticonvulsants Having seizures on average twice a month or more Consent to participate in the study

Exclusion criteria

Exclusion criteria: Concurrent liver and kidney disease and hyperlipidemia Atorvastatin drug use

Design outcomes

Primary

Measure	Time frame
Number of seizure attacks. Timepoint: Before and after the intervention. Method of measurement: Seizure attack frequency.;EEG changes. Timepoint: Before and after the intervention. Method of measurement: Electrocardiogram (ECG).	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMohammad Reza Najafi

Esfahan University of Medical Sciences

Najafi@med.mui.ac.ir+98 31 3620 2020

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026